Halazepam Stats & Data

Halazepam is an oral benzodiazepine that is converted hepatically to the long-acting active metabolite desmethyldiazepam (a.k.a. nordazepam), which has a very long and variable elimination half-life; this can cause next-day psychomotor impairment and cumulative sedation over repeated doses. To reduce stacking and accidental overdose, avoid same-day redosing and be especially cautious on consecutive days of use. Combining halazepam with other central nervous system depressants (alcohol, opioids, GHB/GBL, Z-drugs, barbiturates) markedly increases the risk of profound sedation, respiratory depression, aspiration, and death; such combinations should be avoided. Older adults and people with liver impairment are at higher risk for prolonged sedation, confusion, and falls; smaller test doses and longer spacing between doses reduce risk. Do not abruptly stop after days to weeks of daily or near-daily use; benzodiazepine withdrawal can include anxiety rebound, insomnia, tremor, and in severe cases seizures; gradual tapering is safer than sudden cessation. Driving and operating machinery should be avoided at least until the following day and longer if residual effects persist, as long-acting metabolites can impair reaction time and memory. In pregnancy and lactation, benzodiazepines and their long-acting metabolites can accumulate in the neonate and breastfed infant; if exposure occurs, monitor infants for sedation, poor feeding, and hypotonia. Snorting or injecting crushed tablets or powders provides no established benefit, increases harm, and may introduce insoluble binders; oral administration is the least risky ROA for pharmaceutical benzodiazepines. Use of CYP2C19 or CYP3A4 inhibitors (or poor-metabolizer genotypes) can increase desmethyldiazepam exposure by analogy with diazepam and clorazepate; consider this when other medications or grapefruit-like foods are involved.